280Bio Provides Update on the KRAS Inhibitor TEB-17231 at the 2023 AACR Annual Meeting (PRNewswire) - Mar 21, 2023 - "280Bio, Inc...announced a presentation featuring the Company's lead development candidate TEB-17231 at the AACR Annual Meeting in Orlando, Florida to be held April 14-19, 2023....The presentation describes preclinical findings on a lead series of small molecule inhibitors directed against multiple KRAS-mutation-altered tumor cell lines. The lead candidate TEB-17231 showed robust tumor growth inhibition, against KRASG12V, KRASG12C, KRASG12D and other RAS mutant tumor cell lines. TEB-17231 was also shown to be active in blocking tumor growth in KRASG12C-resistant cell lines bearing different secondary mutations in KRAS. With its excellent pharmacologic properties, TEB-17231 oral dosing demonstrates strong inhibition of in vivo KRAS mutant xenograft tumor growth."
Preclinical • Oncology
|